Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 06, 2020 13:00 ET | Source: MacroGenics, Inc.

MacroGenics Presents Flotetuzumab Data in Patients with Refractory Acute Myeloid Leukemia at the 2020 ASH Annual Meeting

31.8% CR/CRh/CRi rate in primary induction failure and early relapsed AML patientsMedian duration of response = 8.13 months ROCKVILLE, MD, Dec. 06, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc....
November 30, 2020 16:30 ET | Source: MacroGenics, Inc.

MacroGenics and EVERSANA Announce Agreement to Support the Potential Launch and Commercialization of Margetuximab

MacroGenics accesses EVERSANA’s full suite of commercial services for which both parties share expensesEVERSANA may earn revenue share payments over five years subject to predefined capMacroGenics’...
November 30, 2020 07:30 ET | Source: MacroGenics, Inc.

MacroGenics Announces Achievement of $25 Million in Milestones Related to Retifanlimab Collaboration with Incyte

ROCKVILLE, MD, Nov. 30, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal...
November 09, 2020 17:00 ET | Source: MacroGenics, Inc.

MacroGenics to Participate in Upcoming Investor Conferences

ROCKVILLE, MD, Nov. 09, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal...
November 04, 2020 16:01 ET | Source: MacroGenics, Inc.

MacroGenics Provides Update on Corporate Progress and Third Quarter 2020 Financial Results

ROCKVILLE, Md., Nov. 04, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal...
November 04, 2020 14:30 ET | Source: MacroGenics, Inc.

MacroGenics Announces Flotetuzumab and Tebotelimab Presentations at the ASH Annual Meeting 2020

ROCKVILLE, MD, Nov. 04, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal...
October 28, 2020 16:30 ET | Source: MacroGenics, Inc.

MacroGenics Announces Date of Third Quarter 2020 Financial Results Conference Call

ROCKVILLE, MD, Oct. 28, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal...
October 15, 2020 16:30 ET | Source: MacroGenics, Inc.

MacroGenics Announces Flotetuzumab Publication in Blood Advances

ROCKVILLE, MD, Oct. 15, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal...
September 23, 2020 07:15 ET | Source: MacroGenics, Inc.

MacroGenics Announces MGC018 Publication in Molecular Cancer Therapeutics

Manuscript describes preclinical development of MGC018Phase 1 dose expansion trial evaluating MGC018 in patients with mCRPC, TNBC and NSCLC is currently recruiting patients ROCKVILLE, MD,...
September 22, 2020 16:30 ET | Source: MacroGenics, Inc.

MacroGenics Announces Publication of Flotetuzumab Interim Phase 1/2 Clinical Trial Results in Blood

ROCKVILLE, MD, Sept. 22, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal...